301206 三元生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.1962.0942.3251.2235.778
总资产报酬率 ROA (%)1.1331.9822.1841.1575.033
投入资产回报率 ROIC (%)1.1742.0372.2331.1775.209

边际利润分析
销售毛利率 (%)17.59416.11811.1063.05014.055
营业利润率 (%)13.40816.17217.94711.70927.567
息税前利润/营业总收入 (%)13.95315.45116.57710.20518.896
净利润/营业总收入 (%)11.75614.05614.72211.20824.253

收益指标分析
经营活动净收益/利润总额(%)57.84732.05614.140-87.35749.978
价值变动净收益/利润总额(%)43.23666.28284.692189.98946.829
营业外收支净额/利润总额(%)0.0360.3680.2030.566-1.140

偿债能力分析
流动比率 (X)7.23118.34013.9041.4353.226
速动比率 (X)6.36616.86013.3190.9702.759
资产负债率 (%)6.4604.0676.5355.6665.116
带息债务/全部投入资本 (%)0.3990.4191.9903.4332.212
股东权益/带息债务 (%)24,616.84423,399.6754,850.0412,783.6894,380.713
股东权益/负债合计 (%)1,448.0392,358.8281,430.1231,664.8551,854.666
利息保障倍数 (X)25.832-19.783-11.787-6.498-2.260

营运能力分析
应收账款周转天数 (天)33.71956.19249.88646.74651.305
存货周转天数 (天)95.889104.82770.16774.75064.836